Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock Has Consensus Price Target of $34.58 According to Analysts
MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has received a consensus "Hold" rating from analysts, with an average 12-month price target of $34.58. The company recently surpassed quarterly earnings expectations, reporting an adjusted loss of $0.90 per share against an anticipated $1.22 loss, and revenues of $214 million, a 28.5% increase year-over-year. Despite mixed recent analyst actions, institutional investors hold a significant 97.67% of the company's shares.
Read the full story
This is a short summary. The complete article is published by MarketBeat.
Headline and summary aggregated from public news feeds. For information only — not financial advice.